Changchun Gaoxin down 4.44% western Securities Dongguan securities at its highs sing long

2022-05-08 0 By

China Economic Network Beijing, March 25 – Changchun High-tech (000661.SZ) fell today, as of the close, the stock reported 166.70 yuan, down 4.44%.Changchun Gaoxin in May 17, 2021 intraday hit the highest point since the listing of 523 yuan, and Western Securities, Dongguan Securities in April 30, 2021, May 24, 2021, respectively issued a research report sing more changchun Gaoxin.On April 30, 2021, Western Securities published a research report “Changchun Gaoxin (000661) Quarterly Review: High Growth Growth Hormone exceeds expectations in the first quarter”, with researcher Wu Tianhao.According to the research report, the company released the quarterly report of 2021, realizing the revenue of 2.281 billion yuan, up 37.35% year on year;The mother’s net profit was 875 million yuan, up 61.21% year on year;Deduction of non-return parent net profit of 872 million yuan, a year-on-year increase of 60.48%, EPS of 2.16 yuan.Kinsey surpasses expectations with new indication for growth hormone.In Q1 2021, Kinsai Pharmaceutical achieved revenue of 1.843 billion yuan, up 49.7% year-on-year, and net profit of 878 million yuan, up 70% year-on-year.Bacco bio is growing fast, and the new nasal spray flu vaccine is worth looking forward to.In the first quarter of 2021, Baike Biology achieved operating revenue of 250 million yuan, up 24% year-on-year, and net profit of 0.6 billion yuan, up 22% year-on-year.According to Western Securities, changchun Gaoxin is forecast to have a revenue of 115.18/141.22/168.40 billion yuan in 2021, a net profit of 40.65/51.62/6.329 billion yuan and EPS of 10.04/12.76/15.64 yuan.It has a “buy” rating.On May 24, 2021, Dongguan Securities published a research report “Changchun High-tech (000661) : The Growth of the Company will not change as major Shareholders reduce Their Holdings”. The researcher was Wei Hongmei.The research report said that the company is the leader of growth hormone, the domestic market space is large, the competition pattern is good.The major shareholder’s reduction of the company’s shares is mainly due to personal capital needs, and the company’s future growth prospects remain unchanged.Dongguan Securities expects the company’s earnings per share in 2021-2022 to be 9.75/12.27 yuan, and the current stock price is 52/41 times of PE, maintaining its “recommendation” rating on the company.